The treatment of steroid-induced bone loss in transplantation

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Osteopenia after transplantation is a significant cause of morbidity. Despite the lack of randomized, placebo-controlled trials in renal transplantation, there is literature supporting both the prevention and treatment of existing corticosteroid-induced osteoporosis with antiresorptive agents, such as calcitonin and bisphosphonates. The newer pharmacologic agents, nasal spray calcitonin and alendronate, have shown promising results in postmenopausal osteoporosis, and their ease of administration and low incidence of side effects make them ideal for renal transplant patients.

Original languageEnglish
Pages (from-to)544-549
Number of pages6
JournalCurrent Opinion in Nephrology and Hypertension
Volume6
Issue number6
StatePublished - 1997

Fingerprint

Calcitonin
Transplantation
Steroids
Bone Density Conservation Agents
Nasal Sprays
Bone and Bones
Alendronate
Postmenopausal Osteoporosis
Metabolic Bone Diseases
Diphosphonates
Kidney Transplantation
Osteoporosis
Adrenal Cortex Hormones
Randomized Controlled Trials
Placebos
Morbidity
Transplants
Kidney
Incidence
Therapeutics

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

The treatment of steroid-induced bone loss in transplantation. / Moe, Sharon.

In: Current Opinion in Nephrology and Hypertension, Vol. 6, No. 6, 1997, p. 544-549.

Research output: Contribution to journalArticle

@article{d3d73205efc641569bb84051dfb72e23,
title = "The treatment of steroid-induced bone loss in transplantation",
abstract = "Osteopenia after transplantation is a significant cause of morbidity. Despite the lack of randomized, placebo-controlled trials in renal transplantation, there is literature supporting both the prevention and treatment of existing corticosteroid-induced osteoporosis with antiresorptive agents, such as calcitonin and bisphosphonates. The newer pharmacologic agents, nasal spray calcitonin and alendronate, have shown promising results in postmenopausal osteoporosis, and their ease of administration and low incidence of side effects make them ideal for renal transplant patients.",
author = "Sharon Moe",
year = "1997",
language = "English",
volume = "6",
pages = "544--549",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The treatment of steroid-induced bone loss in transplantation

AU - Moe, Sharon

PY - 1997

Y1 - 1997

N2 - Osteopenia after transplantation is a significant cause of morbidity. Despite the lack of randomized, placebo-controlled trials in renal transplantation, there is literature supporting both the prevention and treatment of existing corticosteroid-induced osteoporosis with antiresorptive agents, such as calcitonin and bisphosphonates. The newer pharmacologic agents, nasal spray calcitonin and alendronate, have shown promising results in postmenopausal osteoporosis, and their ease of administration and low incidence of side effects make them ideal for renal transplant patients.

AB - Osteopenia after transplantation is a significant cause of morbidity. Despite the lack of randomized, placebo-controlled trials in renal transplantation, there is literature supporting both the prevention and treatment of existing corticosteroid-induced osteoporosis with antiresorptive agents, such as calcitonin and bisphosphonates. The newer pharmacologic agents, nasal spray calcitonin and alendronate, have shown promising results in postmenopausal osteoporosis, and their ease of administration and low incidence of side effects make them ideal for renal transplant patients.

UR - http://www.scopus.com/inward/record.url?scp=0030783337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030783337&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 544

EP - 549

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 6

ER -